Principles of surgical resection in hilar cholangiocarcinoma

The aim of this article is to describe the surgical techniques for the treatment of hilar cholangiocarcinoma(HC).Resection with microscopically negative margin(R0) is the only way to cure patients with HC.Today,resection of the caudate lobe and part of segment Ⅳ,combined with a right or left hepatectomy,bile duct resection,lymphadenectomy of the hepatic hilum and sometimes vascular resection,is the standard surgical procedure for HC.Intraoperative frozen-section examination of proximal and distal biliary margins is necessary to confirm the suitability of resection.Although lymphadenectomy probably has little direct effect on survival,inaccurate staging information may influence post resection treatment recommendations.Aggressive venous and arterial resections should be undertaken in selected cases to achieve a R0 resection.The concept of "no-touch proposed" in 1999 by Neuhaus et al combine an extended right hepatectomy with systematic portal vein resection and caudate lobectomy avoiding hilar dissection and possible intraoperative microscopic dissemination of cancer cells.More recently minor liver resections have been proposed for treatment of HC.As the hilar bifurcation of the bile ducts is near to liver segments Ⅳ,Ⅴ and Ⅰ,adequate liver resection of these segments together with the bile ducts can result in cure.     

局部晚期肝门部胆管癌根治术后放射治疗

Objective： To evaluate the outcome of radiotherapy （RT） in locally advanced hepatic hilar cholangiocarcinoma. Methods： During March 1992 to December 1997, 47 patients who had positive microscopic surgical margins after surgery were treated by postoperative radiotherapy （S＋RT, 28 patients, with a median dose of 50 Gy, 45-62 Gy） and surgery alone （S, 19 patients）. The median follow-up was 30 months （4-113 months）. Results： The overall 5-year survival rate was 28%, with a median survival length of 19.6 months while 5-year survival rates of S＋RT group and S group were 34% and 14%, with median survival lengths of 29 and 10 months respectively （P=0.015）. The occurrence rate of complications was 11% in either group. Conclusion： Postoperative radiotherapy significantly prolongs survival lengths in patients with hepatic hilar cholangiocarcinoma who had positive microscopic surgical margins. Radiation toxicities are tolerable.     

肝尾叶肝癌28例的手术切除体会

Ofbjective:To analyze the operative technique and results of the resection for caudate lobe carcinoma of the liver. Methods:The liver was fully freed of the ligments,short hepatic veins were divided and sutured,and the tumor was then freed frum the inferior vena cava(IVC).The caudate lobe was resected alone or in combination with other segment. Results:28 patients underwent resection of caudate lobe tumor.The number of the short hepatic veins transected and tied was 2-5(mean 3).An intermittent Pringle‘s manoeuver was used in 26patients with a median occlusion time of 21.7(range10-32)min.The median blood loss was 574(range100-1300)ml.No major complications such as massive bleeding and diliary fistula occurred.Intraoperative total vascular occlusion was perfored on lnly 5 cases.All patients were discharged from the hospital.Outpatient periodic TAEplus chemotherapy was performed.Postoperative recurence and metastasis was found in 13 cases,with 5 deaths. Conclusion:The use of third porta hepatis dissection for resection of the caudate lobe tumor can reduce the risk of massive bleeding during the operation and can raise the rate of resection of caudate lobe tumor.     

"Three-Grade Criteria" of Radical Resection for Primary Liver Cancer

OBJECTIVE The present study was designed to develop the "ThreeGrade Criteria" for radical resection of primary liver cancer (PLC) and to evaluate its clinical significance.METHODS Criteria for radical resection of PLC were summed up to 3 grades based on criterion development. Grade I: complete removal of all gross tumors with no residual tumor at the excision margin. Grade Ⅱ: on or the primary branches of the portal vein, the common hepatic duct or its dition to the above criteria, negative postoperative follow-up result including AFP dropping to a normal level (with positive AFP before surgery)within 2 months after operation, and no residual tumor upon diagnostic imaging.The clinical data from 354 patients with PLC who underwent hepatectomy were reviewed retrospectively. Based on the "Three-Grade Criteria" these patients were divided into 6 groups: Grade Ⅰ radical group,Grade Ⅰ palliative group, Grade Ⅱ radical group, Grade Ⅱ palliative group,Grade Ⅲ radical group, Grade Ⅲ palliative group. The survival rate of each group was calculated by the life-table method and the rates compared among the groups.RESULTS The survival rate of patients receiving radical treatment was better than those receiving palliative treatment (P＜0.01). Survival improved as more criteria were applied. The 5-year survival rate of the patients in Grade Ⅰ, Ⅱ and Ⅲ who underwent radical resection was 43.2%,51.2% and 64.4%, respectively (P＜0.01).CONCLUSION The "Three-Grade Criteria" may be applied for judging the curability of resection therapy for PLC. The stricter the criterion used,the better the survival would be. Adopting high-grade criteria to select cases and guide operations and strengthening postoperative follow-up would improve the results of hepatectomy for PLC.     

“Three-Grade Criteria” of Radical Resection for Primary Liver Cancer

OBJECTIVE The present study was designed to develop the “Three- Grade Criteria” for radical resection of primary liver cancer （PLC） and to evaluate its clinical significance. METHODS Criteria for radical resection of PLC were summed up to 3 grades based on criterion development. Grade Ⅰ： complete removal of all gross tumors with no residual tumor at the excision margin. Grade Ⅱ： on the basis of Grade Ⅰ, additional 4 requirements were added： （1） the tumor was not more than two in number; （2） no tumor thrombi in the main trunks or the primary branches of the portal vein, the common hepatic duct or its primary branches, the hepatic veins or the inferior vena cava; （3）no hilar lymph nodes metastases; （4）no extrahepatic metastases. Grade Ⅲ ： in addition to the above criteria, negative postoperative follow-up result including AFP dropping to a normal level （with positive AFP before surgery） within 2 months after operation, and no residual tumor upon diagnostic imaging.The clinical data from 354 patients with PLC who underwent hepatectomy were reviewed retrospectively. Based on the “Three-Grade Criteria” these patients were divided into 6 groups： Grade Ⅰ radical group, Grade Ⅰ palliative group, Grade Ⅱ radical group, Grade Ⅱ palliative group, Grade Ⅲ radical group, Grade Ⅲ palliative group. The survival rate of each group was calculated by the life-table method and the rates compared among the groups. RESULTS The survival rate of patients receiving radical treatment was better than those receiving palliative treatment （P〈0.01）. Survival improved as more criteria were applied. The 5-year survival rate of the patients in Grade Ⅰ, Ⅱ and Ⅲ who underwent radical resection was 43.2%, 51.2% and 64.4%, respectively （P〈0.01）. CONCLUSION The “Three-Grade Criteria” may be applied for judging the curability of resection therapy for PLC. The stricter the criterion used, the better the survival would be. Adopting high-grade criteria to select cases and guide operations and strengthening postoperative follow-up would improve the results of hepatectomy for PLC.     

Clinical outcomes of gastrointestinal stromal tumor in southern Thailand

AIM: To review a single institutional experience in clinical management of gastrointestinal stromal tumors (GIST) and analyze for factors determining treatment outcome. METHODS: Clinicopathological data of patients with a diagnosis of GIST who were treated at our institute during November 2004 to September 2009 were retrospectively reviewed. RESULTS: Ninety-nine cases were included in the analysis. Primary tumor sites were at the stomach in and small bowel in 44% and 33%, respectively. Thirty-one cases already had metastasis at presentation and the most common metastatic site was the liver. Sixty-four cases (65%) were in the high-risk category. Surgical treatment was performed in 77 cases (78%), 3 of whomreceived upfront targeted therapy. Complete resection was achieved in 56 cases (73% of operative cases) and of whom 27 developed local recurrence or distant metastasis at a median duration of 2 years. Imatinib was given as a primary therapy in unresectable cases (25 cases) and as an adjuvant in cases with residual tumor (21 cases). Targeted therapy gave partial response in 7 cases (15%), stable disease in 27 cases (57%) and progressive disease in 13 cases (28%). Four-year overall survival was 74% (95% CI: 61%-83%). Univariate survival analysis found that low-risk tumor, gastric site, complete resection and response to imatinib were associated with better survival. CONCLUSION: The overall outcomes of GIST can be predicted by risk-categorization. Surgery alone may not be a curative treatment for GIST. Response to targeted therapy is a crucial survival determinant in these patients.     

Pancreatic cancer–Palliative therapy: stenting

Pancreatic cancer remains a common and very lethal malignancy with a median survival of approximately 6 months. Surgical resection offers the only potentially curative approach but many patients (80% or more) are ineligible for this kind of therapy, because of age, comorbidities, or locally advanced or metastatic disease that does not benefit from resection. Thus, for many patients with pancreatic cancer treatment remains palliative and endoscopic therapy to relieve bile duct or gastric outlet obstruction becomes of special importance. Although both surgical and non surgical palliative procedures can relieve biliary and duodenal obstruction particularly endoscopic treatment with plastic prostheses or self expanding metal stents was shown to be not only highly effective but also to be burdened with only few complications. The present article summarizes the palliative endoscopic treatment in patients with non resectable pancreatic cancer.     

SURGICAL TREATMENT OF HILAR BILE DUCT CARCINOMA

From June, 1986 to June 1989, 24 cases of hilar bile duct carcinoma were explored in the Surgical Department of General Hospital of PLA, 16/24 cases were resected, a resectability rate of 66%. The increase of resectability rate was due to earlier recognition of this condition and the extension of surgery, including major resection of liver as well as radical dissection of the hepato-duodenal ligament and repairative operations on the blood vessels. Among these 16 cases, major hepatic resection was performed in 10 cases, in which, 3 cases of resections of the middle lobe of the liver were done instead of right or extended right lobectomy. No operative mortality in the 30 days' postoperative period, but the postoperative morbidity rate was still high and most of the complications were related to biliary leakage and infection. Three patients died in the follow up period at 6, 14 and 15 months respectively. All of them died from biliary infection. The remaining 13 patients were still alive, the longest bein     

表浅型食管癌经内镜黏膜下剥离术导致非治愈性切除的危险因素及长期生存分析

Objective To identify risk factors of non-curative resection in superficial esophageal cancer (SEC) after endoscopic submucosal dissection and to evaluate the prognosis. Methods We retrospectively analyzed the data of 207 SEC patients who received ESD. The median follow-up was 48 months. Results The en bloc resection rate was 89.25% (191/214), the complete resection rate was 80.84 % (173/214), the curative resection rate was 70.09% (150/214) and the non-curative resection rate was 29.91% (64/214). The maximum long diameter of specimen was 110 mm. Age, gender, tumor size, lesions performance during surgery and operation time were associated with the non-curative resection (P<0.05). Female, lesion diameter≥50mm and poorly performed lesions were identified as significant risk factors for non-curative resection. In the noncurative resection group, there was no difference in cancer-free survival and survival between patients who had no additional treatmeat after ESD and those who underwent surgery or radiotherapy. Conclusion For patients with poor general condition who are not willing to undergo surgery or chemoradiotherapy, regular endoscopy seems to be an option. © 2020, CHINA RESEARCH ON PREVENTION AND TREATMENT. All rights reserved.     

Hilar Cholangiocarcinoma with Synchronous Metastases to Breast and Skeletal Muscle： A Case Report and Literature Review

Hilar cholangiocarcinoma has been reputed as a slow growth tumor in the past. Skeletal muscle is one of the most unusual sites of metastasis from any malignancy. We report herein a case of hilar cholangiocarcinoma with synchronous metastases to skeletal muscle and breast, and review the literature. The patient was a 48-year-old woman who presented with jaundice and weight loss. An inoperable hilar cholangiocarcinoma was diagnosed. She was treated with a combination of endoscopic plastic stent biloiary drainage and three-dimensional conformal radiotherapy （3DCRT）. Good response was achieved. Ten months later, she exhibited with a painful metastatic mass in the muscle rectus femoris of left thigh and a painless mass in the left breast. She underwent operation to relieve the pain, but died from liver failure after 8 months. The literature only offers isolated cases of cholangiocarcinoma with distant metastases, of which the common sites were cervical lymph node, bone, and portal venous system. Most patients were presented with multiple metastases with extensive local disease.     

Extended right hepatectomy for hilar cholangiocarcinoma with resection of the left hepatic duct prior to hepatic resection

Extended hepatectomy for hilar cholangiocarcinoma results in high operative or in-hospital mortality rates despite of the recent progress in perioperative management. As a new procedure to prevent postoperative hepatic failure in hilar cholangiocarcinoma infiltrating predominantly the right hepatic duct, we devised a combination of extended right lobectomy plus caudal lobectomy with resection of the left hepatic duct prior to hepatic resection by utilizing intraoperative cholangiography, and applied the procedure to a 70-year-old patient. He had a favorable postoperative course and remains recurrence-free at 4 years after operation. This is a procedure for confining the extent of hepatectomy to the minimum necessary, aiming at curative resection of hilar cholangiocarcinoma.     

外科治疗肝门部胆管癌68例临床分析

目的：探讨提高肝门部胆管癌尤其是肝门部血管受肿瘤侵犯病例的外科治疗方法。方法：回顾性分析我院1986年1月～2004年12月收治手术的肝门部胆管癌68例。结果：按Bismuth-Corlette分型法：Ⅰ型7例,Ⅱ型15例,ⅢA型19例,ⅢB型12例,Ⅳ型15例（包括不能分型3例）。26例（38.24%）确诊前曾有胆囊结石和/或肝内外胆管结石手术史,或同时合并有胆石症。B超、CT和MRCP的确诊率分别为71.43%、84.00%和91.43%。手术方式：根治性切除24例,姑息性切除14例,胆道引流30例。术后1、2、3年生存率：根治性切除组分别为85.0%（17/20）、60.0%（12/20）和25.0%（5/20）,其中3例生存时间超过5年;姑息性切除组分别为58.3%（7/12）、25.0%（3/12）和0,两组之间的3年生存率比较有显著性差异（P〈0.05）;胆道引流组1、2、3年生存率分别为21.4%（6/28）、10.7%（3/28）和0。结论：积极提高手术切除率是改善肝门部胆管癌预后的惟一有效方法;肝十二指肠韧带骨髂化、肝部分切除可提高根治性切除率。姑息性切除、胆道引流有助于改善患者生活质量,延长生存。     

肝门扣式吻合术在治疗Ⅲ型和Ⅳ型肝门部胆管癌中的临床价值

目的 探讨肝门扣式吻合术在治疗Ⅲ型和Ⅳ型肝门部胆管癌中的临床应用价值.方法 回顾性分析1990年1月至2008年1月间接受手术治疗的89例Ⅲ型和Ⅳ型肝门部胆管癌患者的临床资料.以2000年1月(开始采用肝门扣式吻合术)为界,将患者分为两个治疗阶段,比较两个阶段Ⅲ型和Ⅳ型肝门部胆管癌患者的手术切除率,并分析肝门扣式吻合术的治疗效果和并发症.结果 第一阶段治疗胆管癌患者37例,手术切除4例(10.8%),其中根治性切除1例(2.7%),姑息性切除3例(8.1%).第二阶段治疗胆管癌患者52例,手术切除35例(67.3%),其中根治性切除15例(28.8%),姑息性切除20例(38.5%).第二阶段接受手术切除治疗的35例患者中,有28例(80.0%)采用肝门扣式吻合的手术方式.统计结果 显示,无论是根治性切除还是姑息性切除,第二阶段Ⅲ型和Ⅳ型患者的手术切除率均高于第一阶段患者(均P<0.05).89例患者中,术后并发腹腔积液3例,胆道出血1例,心功能衰竭1例,伤口感染2例.采用肝门扣式吻合术的患者术后均出现不同程度的胆瘘,经引流和对症治疗后痊愈.结论 肝门扣式吻合术可提高Ⅲ型和Ⅳ型肝门部胆管癌的切除率,是一种新的可供选择的治疗方法 ,但其远期治疗效果有待进一步研究和随访.     

Ⅲ Ⅳ型肝门胆管癌扩大肝切除临床疗效分析*

目的:探讨扩大肝切除对Bismuth-Corlette Ⅲ、Ⅳ型肝门胆管癌的临床疗效。方法:回顾性分析蚌埠医学院第一附属医院2008年1 月至2015年5 月61例Bismuth-Corlette Ⅲ、Ⅳ型肝门部胆管癌患者的临床资料。其中扩大肝切除组行半肝及以上肝切除和（或）联合尾状叶切除术22例;局限肝切除组行肝门区不规则肝切除术39例。结果:扩大肝切除组患者相比局限肝切除组手术时间长、术中出血量多。扩大肝切除组患者并发症发生率低于局限肝切除组患者;扩大肝切除组无围手术期死亡患者,局限肝切除组有2 例围手术期死亡患者;扩大肝切除组R 0 切除21例,R 0 切除率为95.5%（21/ 22）,局限肝切除组R 0 切除20例,R 0 切除率为51.3%（20/ 39）,差异具有统计学意义（P < 0.05）;扩大肝切除组1、3、5 年生存率分别是77.27% 、36.36% 、13.64% ;局限肝切除组1、3、5 年生存率分别是69.23% 、20.51% 、1.64% ,差异具有统计学意义（P < 0.05）。 结论:Bismuth-Corlette Ⅲ、Ⅳ型肝门部胆管癌扩大肝切除可以有效提高患者的R 0 切除率和生存率,改善患者的预后。      

联合肝叶切除治疗肝门部胆管癌的疗效分析

背景与目的：肝门部胆管癌(hilar cholangiocarcinoma,HC)侵袭途径广泛以及术后缺乏有效辅助治疗,目前患者获得治愈的惟一途径依然是手术根治性切除。术前可切除性评估、术前胆道引流、肝切除的范围及淋巴结清扫范围等问题一直是研究的热点。本文探讨联合肝叶切除治疗HC的临床经验及疗效。方法：回顾性分析昆明医科大学第一附属医院2007年1月—2013年10月行手术治疗的207例HC患者的临床及随访资料。结果：全组207例患者中,125例行根治性切除(R₀切除),R₀切除率为60.4%。联合肝叶切除156例,肝叶切除组获R0切除率70.5%;51例行单纯性切除,单纯性切除组获R₀切除率29.4%,两组比较R₀切除率差异有统计学意义(P<0.01)。2例患者死于围手术期,术后主要并发症包括肝肾功能不全和胆漏。获得随访的172例中,102例行R₀切除的患者中位生存时间为45个月,术后1、3、5年累积生存率分别为96.1%、59.1%、17.2%,70例行R_1-2切除的患者中位生存时间为26个月,术后1、3年累积生存率分别为81.3%、19.2%,无5年存活患者。获得R₀切除患者术后生存率优于姑息性切除(R_1-2切除)患者,差异有统计学意义(χ²=39.121,P<0.01)。在联合肝叶切除组中获R₀切除患者术后1、3、5年生存率为97.8%、63.9%、18.0%,在单纯性切除组中获R₀切除患者术后1、3、5年生存率为83.3%、20.8%、8.3%,两组术后生存率差异有统计学意义(χ²=5.988,P=0.014)。结论：根治性切除是提高HC远期疗效的关键,联合肝叶切除及标准化淋巴结清扫可显著提高HC的根治性切除率及远期疗效。     

Surgical strategy for bile duct cancer: Advances and current limitations

The aim of this review is to describe recent advances and topics in the surgical management of bile duct cancer. Radical resection with a microscopically negative margin (R0) is the only way to cure cholangiocarcinoma and is associated with marked survival advantages compared to margin-positive resections. Complete resection of the tumor is the surgeon's ultimate aim, and several advances in the surgical treatment for bile duct cancer have been made within the last two decades. Multidetector row computed tomography has emerged as an indispensable diagnostic modality for the precise preoperative evaluation of bile duct cancer, in terms of both longitudinal and vertical tumor invasion. Many meticulous operative procedures have been established, especially extended hepatectomy for hilar cholangiocarcinoma, to achieve a negative resection margin, which is the only prognostic factor under the control of the surgeon. A complete caudate lobectomy and resection of the inferior part of Couinaud's segment IV coupled with right or left hemihepatectomy has become the standard surgical procedure for hilar cholangiocarcinoma, and pylorus-preserving pancreaticoduodenectomy is the first choice for distal bile duct cancer. Limited resection for middle bile duct cancer is indicated for only strictly selected cases. Preoperative treatments including biliary drainage and portal vein embolization are also indicated for only selected patients, especially jaundiced patients anticipating major hepatectomy. Liver transplantation seems ideal for complete resection of bile duct cancer, but the high recurrence rate and decreased patient survival after liver transplant preclude it from being considered standard treatment. Adjuvant chemotherapy and radiotherapy have a potentially crucial role in prolonging survival and controlling local recurrence, but no definite regimen has been established to date. Further evidence is needed to fully define the role of liver transplantation and adjuvant chemo-radiotherapy.     

联合肝叶切除的肝门部胆管癌R0级根治术明显延长患者生存期

目的：本文通过分析单个医学中心5年期间所实施的肝门部胆管癌手术治疗病例资料,确定影响患者术后生存的因素。方法：收集并分析西安交通大学医学院第一附属医院肝胆外科2003-2007年实施102例肝门部胆管癌根治术患者的临床资料,通过统计学方法分析影响患者术后生存期的因素。结果：25例（24.5%）患者入院时丧失接受根治性手术机会,仅行PTBD减黄治疗。77例患者接受开腹手术治疗,67例（87.0%）患者接受根治性切除,其中51例（76.1%）患者术后证实达到R0级。接受开腹手术患者术后1月的并发症发生率为20.8%,术后1月无患者死亡。单因素分析发现联合肝叶切除的根治术、R0级根治术、较好的肿瘤分化程度、肿瘤大小和未发生淋巴结肿瘤转移均影响患者术后的生存期。多因素分析证实联合肝叶切除的根治术和R0级根治术是影响患者术后生存的独立因素。结论：达到R0级的联合肝叶切除的肝门部胆管癌根治术明显延长患者术后生存期,可考虑成为肝门部胆管癌外科治疗的金标准。     

The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: A multi-institutional analysis of 305 cases

BACKGROUND. Surgical strategy for hilar cholangiocarcinoma often includes hepatectomy, but the role of portal vein resection (PVR) remains controversial. In this study, the authors sought to identify factors associated with outcome after surgical management of hilar cholangiocarcinoma and examined the impact of PVR on survival.

METHODS:

Three hundred five patients who underwent curative‐intent surgery for hilar cholangiocarcinoma between 1984 and 2010 were identified from an international, multi‐institutional database. Clinicopathologic data were evaluated using univariate and multivariate analyses.

RESULTS:

Most patients had hilar cholangiocarcinoma with tumors classified as T3/T4 (51.1%) and Bismuth‐Corlette type II/III (60.9%). Resection involved extrahepatic bile duct resection (EHBR) alone (26.6%); or hepatectomy and EHBR without PVR (56.7%); or combined hepatectomy, EHBR, and PVR (16.7%). Negative resection (R0) margin status was higher among the patients who underwent hepatectomy plus EHBR (without PVR, 64.2%; with PVR, 66.7%) versus EHBR alone (54.3%; P < .001). The median number of lymph nodes assessed was higher among the patients who underwent hepatectomy plus EHBR (without PVR, 6 lymph nodes; with PVR, 4 lymph nodes) versus EHBR alone (2 lymph nodes; P < .001). The 90‐day mortality rate was lower for patients who underwent EHBR alone (1.2%) compared with the rate for patients who underwent hepatectomy plus EHBR (without PVR, 10.6%, with PVR, 17.6%; P < .001). The overall 5‐year survival rate was 20.2%. Factors that were associated with an adverse prognosis included lymph node metastasis (hazard ratio [HR], 1.79; P = .002) and R1 margin status (HR, 1.81; P < .001). Microscopic vascular invasion did not influence survival (HR, 1.23; P = .19). Among the patients who underwent hepatectomy plus EHBR, PVR was not associated with a worse long‐term outcome (P = .76).

CONCLUSIONS:

EHBR alone was associated with a greater risk of positive surgical margins and worse lymph node clearance. The current results indicated that hepatectomy should be considered the standard treatment for hilar cholangiocarcinoma, and PVR should be undertaken when necessary to extirpate all disease. Combined hepatectomy, EHBR, and PVR can offer long‐term survival in some patients with advanced hilar cholangiocarcinoma. Cancer 2012. © 2012 American Cancer Society.     

肝门部胆管癌84例临床分析

目的 分析探讨肝门部胆管癌的临床特点和手术治疗效果。方法 回顾性分析84例肝门部胆管癌的临床资料,对其临床分型、不同手术方法及随诊结果进行统计学分析。结果 按Bismuth—Corlette分型法,Ⅰ型7例,Ⅱ型18例,Ⅲa型22例,Ⅲb型12例,Ⅳ型20例,不能分型5例。32例（38．1％）确诊前曾有胆囊结石和（或）肝内外胆管结石手术史,或同时合并有胆石症。B超、CT和磁共振胆胰管成像（MRCP）的确诊率分别为71．4％、84．0％和91．4％。84例唐苦中,根治性切除24例,姑息性切除14例,胆道引流30例;未手术16例。总手术率为81．0％（68／84）根治性切除率为28．6％（24／84）。根治性切除患者的1、2、3年生存率分别为70．8％（17／24）、50．0％（12／24）和20．8％（5／24）,其中3例生存时间超过5年。姑息性切除患者的1、2．3年生存率分别为50．0％（7／14）、21．4％（3／14）和0,两组生存率差异有统计学意义（P〈0．05）;胆道引流患者的1、2、3年生存率分别为20．0％（6／30）、10．0％（3／30）和0,非手术患者平均存活4．3个月,无一例超过1年。结论胆石症可能是肝门部胆管癌的重要诱因;提高手术切除率是改善肝门部胆管癌预后的惟一有效方法,肝十二指肠韧带骨髂化、肝部分切除可提高根治性切除率。